Expand IRD Menu
IRD MENU

IRD Latest Press Releases

-- August 19, 2026 --

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer Globe Newswire 4:05 PM
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- August 6, 2026 --

Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update Globe Newswire 7:00 AM

-- August 3, 2026 --

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease Globe Newswire 7:00 AM

-- July 9, 2026 --

Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results Globe Newswire 7:00 AM

-- July 6, 2026 --

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease Globe Newswire 7:00 AM

-- June 26, 2026 --

Opus Genetics Added to the Russell 3000, Russell 2000 and Russell Microcap Indexes Globe Newswire 9:15 AM

-- June 16, 2026 --

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases Globe Newswire 4:05 PM

-- June 2, 2026 --

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts Globe Newswire 7:00 AM

-- May 28, 2026 --

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- May 27, 2026 --

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference Globe Newswire 8:00 AM

-- May 13, 2026 --

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference Globe Newswire 7:00 AM

-- May 12, 2026 --

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update Globe Newswire 7:00 AM

-- May 7, 2026 --

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases Globe Newswire 4:30 PM
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study Globe Newswire 7:00 AM

-- May 4, 2026 --

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program Globe Newswire 4:30 PM

-- April 27, 2026 --

Opus Genetics to Participate in Leading Medical Conferences in May 2026 Globe Newswire 8:00 AM

-- April 10, 2026 --

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting Globe Newswire 6:59 AM

-- April 6, 2026 --

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes